Log In
Print this Print this

Renal cancer assay

  Manage Alerts
Collapse Summary General Information
Company Genomic Health Inc.
DescriptionPrognostic test to analyze multi-gene expression and estimate recurrence risk following surgery
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPilot
Standard IndicationCancer, Diagnostic
Indication DetailsEstimate risk of recurrence following surgery to help identify early stage patients with renal cell carcinoma (RCC) that could benefit most from treatment
Regulatory Designation
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today